The prices of drugs and the innovation that leads to their availability are reliable sources of controversy in American public discourse. In 2023, the United States spent $723...
In the span of a single week in late January and early February 2026, 3 federal actions—by Congress, the Department of Labor (DOL), and the Federal Trade Commission...
We follow 19 biopharma companies that have had or are likely to have a drug selected for Medicare negotiation as a result of the Inflation Reduction Act (IRA)...
On August 29, the Centers for Medicare & Medicaid Services announced the first 10drugs to be negotiated by Medicare. As CMS and pharmaceutical manufacturersprepare for negotiations, they will...
Though there was optimism coming into 2025 that conditions were improving for the industry due to growing M&A interest and hopes for monetary easing, the uncertainty created by...
Partner with Verdant for rigorous, objective economic analysis.